Translational and Commercialization Benefits
Platform |
Medical and Scientific Focus |
Translational Benefits |
Commercialization Benefits |
Develop platform with: improved imaging probe discovery; in vitro screening program; and enhanced throughput in vivo screening to accelerate discovery and validation of novel cancer imaging biomarkers for preclinical and clinical applications. |
Discovery of more sensitive and specific novel cancer imaging biomarkers for single and multi-modality imaging (CT, PET, SPECT, MR/S, US) that improve earlier detection and diagnosis, and ultimately, improved long term cancer-free survival. |
|
|
Develop open source image viewing processing platforms to integrate and analyze images from different modalities. Develop 3D multi-modality needle guidance tools allowing biopsy of tissues identified with novel imaging probes |
Open source software enables implementation in research and hospital setting. Improved prostate biopsy planning. Improved intra-procedural 3D transrectal ultrasound prostate biopsy guidance. Improved biopsy and repeat biopsy accuracy to 2mm in humans. |
The 3D acquisition, reconstruction and segmentation modules have been patented. Patents have been filed describing the trans-perineal biopsy and therapy approach. |
|
Whole-mount 3D techniques for pathological assessment using histopathology and molecular pathology approaches. Image registration and analysis tools. |
Improved methods of evaluation of pathological response to treatment. Assessment of markers. Imaging/pathology correlation, validation of new in vivo imaging methods |
Software tools (registration, calibration, display, analysis), tissue processing tools and procedures |
|
|
|
Develop novel tools for clinical trial imaging including an image viewing platform compatible with clinical radiology platform, validated plug-ins and accreditation. |
Image acquisition and analysis, and standardized reports for quantitative measurements that meet clinical trials requirements for existing endpoints (i.e. RECIST). |
Image analysis software for the measurement and quantification of novel imaging biomarkers of tumour response to therapy. |
Establish a clinical trial imaging research network engaged in the application of imaging innovations to clinical trial applications. |
Network enables uniformity of image viewing and analysis tools to measure novel biomarkers of tumour response suitable for use in clinical trials. Development of a tumour image bank as a resource. |
|